NSCLC (Non-small Cell Lung Carcinoma) Clinical Trial
Official title:
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
The primary objectives of this study is to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion).
Sponsor decision to not initiate part 2 of the trial and Part 2 of the study was not
conducted.
In Part 2, the randomized portion, the objective is to evaluate and compare the overall
survival of subjects with previously treated advanced or metastatic non-small cell lung
cancer (NSCLC) when treated with itacitinib in combination with docetaxel versus docetaxel
alone.
The secondary objectives of this study (Part 2) are to evaluate and compare the efficacy of
the 2 treatment groups with respect to progression-free survival, overall tumor response, and
duration of response, and to evaluate and compare disease control, safety, and tolerability
of itacitinib in combination with docetaxel versus docetaxel alone.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02298153 -
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
|
Phase 1 | |
| Terminated |
NCT02119650 -
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02355431 -
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
|
Phase 2 |